

# Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

# ITONIS, INC.

a Nevada corporation 22600-C Lambert Street Suite 902 Lake Forest, CA 92630

(949) 200-8887 www.itonisholdings.com office@itonisholdings.com SIC Code 6719

Quarterly Report
For the Period Ending: August 31, 2021
(the "Reporting Period")

Please note that the number of shares outstanding of our Common Stock has remained *unchanged* since the reporting period ending November 30, 2017: <u>1,523,409,834</u>

As of the current Reporting Period ending **August 31, 2021**, the number of shares outstanding of our Common Stock was: <u>1,523,409,834</u>

As of prior Reporting Period ending **May 31, 2021**, the number of shares outstanding of our Common Stock was: <u>1,523,409,834</u>

As of the most recent completed Fiscal Year End date of **November 30, 2020**, the number of shares outstanding of our Common Stock was: <u>1,523,409,834</u>

Indicate by che	ck mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and
Rule 12b-2 of the	ne Exchange Act of 1934): Yes: □ No: ⊠
Indicate by che	ck mark whether the company's shell status has changed since the previous reporting period:
Yes: □	No: ⊠
Indicate by che	ck mark whether a Change in Control <sup>1</sup> of the company has occurred over this reporting period:
Yes: □	No: ⊠

<sup>&</sup>lt;sup>1</sup> "Change in Control" shall mean any events resulting in:

<sup>(</sup>i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities:

<sup>(</sup>ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

<sup>(</sup>iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

<sup>(</sup>iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

### 1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Itonis, Inc. The company was incorporated as Kenchou, Inc. in Nevada on July 5, 2005. Name changed to Itonis, Inc. on December 2, 2005.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive): <u>July 5, 2005 in Nevada</u>. <u>Status is active</u>.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

### None known.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months: None.

The address(es) of the issuer's principal executive office:

22600-C Lambert Street, Suite 902, Lake Forest, California 92630.

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address:

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years? Yes:  $\square$  No:  $\boxtimes$ 

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below: N/A.

# 2) Security Information

Trading symbol: ITNS
Exact title and class of securities outstanding: Common
CUSIP: 465733103
Par or stated value: \$0.001

Total shares authorized:

Total shares outstanding:

Number of shares in the Public Float<sup>2</sup>:

Total number of shareholders of record:

1,800,000,000

as of date: Aug 31, 2021.

All additional class(es) of publicly traded securities (if any):

Trading symbol:	No other classes of publicly traded securities.
Exact title and class of securities outstanding:	
CUSIP:	

<sup>&</sup>lt;sup>2</sup> "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

	ed value: es authorized: es outstanding:		of date: of date:	<u>—</u>
Total Silait	so outstanding.	as t	Ji date	<del>_</del>
Transfer A	gent			
Name:	Action Stock Transfer Corp.			
Phone:	<u>(801) 274-1088</u>			
Email:	action@actionstocktransfer.com			
Address:	2469 E. Fort Union Blvd, Suite 214,	Salt Lake Cit	<u>y, Utah 84</u>	<u>121</u>
Is the Tran	sfer Agent registered under the Exch	ange Act? <sup>3</sup> `	Yes: ⊠	No: □

# 3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

# A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods:  $\boxtimes$ 

Shares Outsta	anding as of Sec	ond Most							
Recent Fiscal	Year End:								
	Opening	Balance		*Rig	ht-click the rows b	elow and select "Inser	t" to add rows as nee	eded.	
Date <u>11/30/20</u>	017 Common	i: <u>1,523,409,834</u>							
	Preferred	d: <u>500,000</u>							
Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricte d as of this filing.	Exempti on or Registrat ion Type.
Shares Outsta	anding on Date of	of This Report:							
Ending Balance:									
Date <u>8/31/202</u>	21 Common	ı: <u>1,523,409,834</u>							
	Preferre	d: <u>500,000</u>							

<sup>&</sup>lt;sup>3</sup> To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

*Example:* A company with a fiscal year end of December 31<sup>st</sup>, in addressing this item for its quarter ended September 30, 2020, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2018 through September 30, 2020 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above: None

# B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements:

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrue d (\$)	mechanism for determining conversion of instrument to shares)  Noteholder (entities must have individual with voting / investment control disclosed).		(entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
11/30/16	<u>\$7,011.99</u>	\$7,011.99		<u>5/31/17</u>	Discount market share price 50%.	Abraham Abu	Loan.
11/30/16	<u>\$16,600</u>	<u>\$16,600</u>		<u>5/31/17</u>	Discount market share price 50%.	CZA, Inc. (control: Doris Vo)	<u>Loan</u>
<u>2/28/17</u>	\$4,023.98	\$4,023.98		<u>8/31/17</u>	Discount market share price 50%.	Abraham Abu	<u>Loan</u>
2/28/17	<u>\$7,500</u>	<u>\$7,500</u>		8/31/17	Discount market share price 50%.	CZA, Inc. (control: Doris Vo)	Loan
5/31/17	\$24,000	\$24,000		11/30/17	Discount market share price 50%.	CZA, Inc. (control: Doris Vo)	Loan
8/31/17	\$18,500	\$18,500		<u>2/28/18</u>	Discount market share price 50%.	CZA, Inc. (control: Doris Vo)	Loan
2/28/18	<u>\$12,000</u>	<u>\$12,000</u>		8/30/18	Discount market share price 50%.	Charlie Abujudeh	<u>Loan</u>
4/30/18	<u>\$3,760.31</u>	<u>\$3,760.31</u>		10/31/18	Discount market share price 50%.	Charlie Abujudeh	<u>Loan</u>
5/31/18	<u>\$42,000</u>	\$42,000		11/30/18	Discount market share price 50%.	Charlie Abujudeh	<u>Loan</u>
6/30/18	<u>\$5,882</u>	<u>\$5,882</u>		12/31/18	Discount market share price 50%.	Abraham Abu	<u>Loan</u>
8/31/18	\$5,000	\$5,000		3/31/19	Discount market share price 50%.	Charlie Abujudeh	<u>Loan</u>
10/31/18	<u>\$1,800</u>	<u>\$1,800</u>		4/30/19	Discount market share price 50%.	Mark Cheung	<u>Loan</u>
11/30/18	\$13,200	\$13,200		5/31/19	Discount market share price 50%.	Charlie Abujudeh	<u>Loan</u>
2/28/19	<u>\$13,500</u>	\$13,500		8/31/19	Conversion rate of \$0.001 per share.	Charlie Abujudeh	<u>Loan</u>

5/31/19	\$17,000	\$17,000	 11/30/19	Conversion rate of \$0.001 per share.	Intermarket Associates (control: Charlie Abujudeh)	Loan
8/31/19	\$12,000	\$12,000	 2/29/20	Conversion rate of \$0.001 per share.	Intermarket Associates (control: Charlie Abujudeh)	Loan
11/30/19	\$10,000	\$10,000	 5/31/20	Conversion rate of \$0.001 per share.	Intermarket Associates (control: Charlie Abujudeh)	Loan
2/28/20	\$20,014.90	\$20,014.90	 8/31/20	Conversion rate of \$0.001 per share.	Intermarket Associates (control: Charlie Abujudeh)	Loan
8/31/20	<u>\$14,800</u>	<u>\$14,800</u>	 2/28/21	Conversion rate of \$0.001 per share.	Intermarket Associates (control: Charlie Abujudeh)	<u>Loan</u>
11/30/20	<u>\$11,500</u>	<u>\$11,500</u>	 5/30/21	Conversion rate of \$0.001 per share.	Intermarket Associates (control: Charlie Abujudeh)	Loan
2/28/21	\$9,000.	\$9,000.	 8/30/21	Conversion rate of \$0.001 per share.	CZA, Inc. (control: Doris Vo)	<u>Loan</u>
2/28/21	\$3,000.	\$3,000.	 8/30/21	Conversion rate of \$0.001 per share.	Intermarket Associates (control: Charlie Abujudeh)	Loan
5/31/21	\$13,000.	\$13,000.	 5/31/22	Conversion rate of \$0.001 per share.	Intermarket Associates (control: Charlie Abujudeh)	Loan

Use the space below to provide any additional details, including footnotes to the table above: None

# 4) Financial Statements

A. The following financial statements were prepared in accordance with:

☑ U.S. GAAP☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)4:

Name: Michael Berg

Title: <u>CPA</u>
Relationship to Issuer: CPA

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;
- D. Statement of income:
- E. Statement of cash flows;
- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

See said financial statements appended hereto below, and incorporated herein by this reference.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

## 5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

The Company operates as a holding company and has embarked upon an aggressive plan to acquire high growth entrepreneurial companies that have established or are expected to establish themselves as leaders and successful enterprises in various market niches.

B. Please list any subsidiaries, parents, or affiliated companies.

See subsidiary identified in Section C immediately below.

<sup>&</sup>lt;sup>4</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills

#### C. Describe the issuers' principal products or services.

In 2012, the Company launched a new Itonis Pharmaceuticals division headed by Dr. Charles Hensley, Ph.D. to produce and market over the counter and prescription homeopathic preparations to treat both common ailments and chronic diseases. The Company has launched the retails sale of the Emesyl® nausea relief product. The Company has identified the market for its Emesyl® product line as the general public who suffers from nausea. Emesyl® is available for purchase at <a href="https://www.amazon.com/dp/B00U20H3KI">https://www.amazon.com/dp/B00U20H3KI</a> and <a href="https://www.emesyl.com">www.Emesyl.com</a>.

This year 2021, the Company has entered into an agreement with CVS Pharmacy to participate in their Test & Learn Program for our flagship product, Emesyl®. We initially received two purchase orders from CVS which involved shipping Emesyl® products to two CVS distribution centers in Texas. From there, we expect the program to place Emesyl® in 100 retail stores across the country, entering into a 24-week analysis phase. We expect to gather weekly feedback with performance metrics via an online dashboard to develop action plans for sales success. CVS seems to like the uniqueness of Emesyl® with it being "Homeopathic" and the "only fast acting nasal spray" on the market. If the success criteria are met, an action plan will be developed by the CVS category manager to expand distribution to 8000+ stores, which is typically executed in their next CVS planogram cycle. At this moment, we will see what the Test & Learn Program will tell us.

Meanwhile, the Company has organized its Itonis Holdings, Inc. subsidiary to own and manage the entirety of the Emesyl® nausea relief product line. Dr. Hensley has fully assigned all the patent rights in Emesyl® nausea relief to Itonis Holdings, Inc. The Company has organized said pharmaceuticals division and its Emesyl® and Emesyl® Product line within its wholly-owned subsidiary, Itonis Holdings, Inc.

In March 2014, the Company signed a licensing agreement with MyECheck, Inc. for the Company to implement a mobile app for point-of-purchase sales transactions. The Company has determined that the licensing company will not complete the software in accordance with the licensing agreement and is considering the pursuit of its legal rights under the agreement. The Company fully reserved its investment in the licensing agreement during the last quarter of 2017.

### 6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company's corporate headquarters are located in approximately 1,728 square feet of leased office space in Lake Forest, California pursuant to a lease that expires in September 2023. In the opinion of management, the Company's current space is adequate for its operating needs.

# 7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% of more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are** 

corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.

Name of Officer/ Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Mark Cheung	CEO, CFO, Director	Lake Forest, CA	<u>179,458,875</u>	<u>Common</u>	<u>11.8%</u>	
		_	<u>250,000</u>	<u>Preferred</u>	<u>50%</u>	
<u>Steve</u> <u>Pidliskey</u>	Vice President	<u>Lake Forest,</u> <u>CA</u>	99,948,668	Common	6.6%	
Sam Joudeh	<u>Director</u>	Lake Forest, CA	3,000,000	Common	0.2%	
			<u>250,000</u>	<u>Preferred</u>	<u>50%</u>	

## 8) Legal/Disciplinary History

- A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:
  - 1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses); None.
  - 2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities; None.
  - 3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated: or None.
  - 4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities. None.
- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities. None.

# 9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: None.

Firm:	
Address 1:	
Address 2:	
Phone:	
Email:	
Accountant or Auditor	
Name:	Michael Berg
Firm:	
	Berg & Company, CPA
Address 1:	1881 Carignan Way
Address 2:	Yountville, CA 94599
Phone:	<u>(415) 515-4090</u>
Email:	cpaberg@aol.com
Investor Relations	
Name:	None.
Firm:	THORIC.
Address 1:	
Address 1: Address 2:	
Phone:	
Email:	
Other Service Provider	rs
Provide the name of a respect to this disclo	by other service provider(s) that <b>that assisted</b> , <b>advised</b> , <b>prepared or provided information with sure statement</b> . This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided to the issuer during the reporting period.
Name:	None other than the CPA.
Firm:	
Nature of Services:	
Address 1:	
Address 2:	
Phone:	
Email:	
Liliali.	
10) Issuer Certific	cation
Principal Executive Of	ficer & Principal Financial Officer:
I, Mark Cheung, certify	

- 1. I have reviewed this Quarterly disclosure statement] of Itonis, Inc.;
- 2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
- 3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Dec 8, 2021 [Date]

/s/ Mark Cheung [CEO's & CFO's Signature]

# 2021 Quarterly Report

# **ITNS**

Itonis Inc. (formerly "Kenshou Inc.")

For the Period Ending August 31, 2021

THESE UNAUDITED FINANCIAL STATEMENTS ARE INCORPORATED BY REFERENCE INTO THE DISCLOSURE STATEMENT PURSUANT TO THE PINK BASIC DISCLOSURE GUIDELINES

# Itonis Inc.

# **Table of Contents**

# Item 5. Financial Statements

Unaudited Balance Sheets as of August 31, 2021 and 2020

Unaudited Profit and Loss Statements for the Years ended August 31, 2021 and 2020

Unaudited Statements of Shareholders Equity for the Years ended August 31, 2021 and 2020

Unaudited Statements of Cash Flows for the Years ended August 31, 2021 and 2020

Notes to Consolidated Financial Statements

# Itonis Inc. (formerly "Kenshou Inc.") Balance Sheet

# (unaudited)

	August 31, 2021			November 30, 2020		
Current assets Cash Other Assets Total current assets	\$	2,468 2,086 4,554	\$	2,149 2,086 4,235		
Inventory Emesyl Patent		34,034 13,000		36,331 13,000		
Total assets	\$	51,588	\$	53,566		
Liabilities and stockholders' deficit						
Current liabilities Accounts payable and accrued liabilities Accounts payable - related parties Derivative liability Loan payable Income taxes payable Total current liabilities  Long Term liabilities	\$	229,249 3,360 900,441 5,600 1,138,650	\$	229,249 960 870,441 5,600 1,106,250		
_		4 400 050		4 400 000		
Total liabilities  Stockholders' deficit  Preferred stock; no par;  \$.001 par; 5,000,000 authorized; and 500,000 issued and outstanding  Common stock;  \$.001 par; 1.800,000,000 authorized; 1,523.409,834 issued and outstanding  Additional paid-in capital  Accumulated deficit  Total stockholders' deficit		1,138,650 500 1,523,410 13,513,059 (16,124,031) (1,087,062)		1,106,250 500 1,523,410 13,513,059 (16,089,653) (1,052,684)		
Total liabilities and stockholders' deficit	\$	51,588	\$	53,566		

# Itonis Inc. (formerly "Kenshou Inc.") Income Statements (unaudited)

	For the Three August 31, 2021	Months Ended August 31, 2020	For the Nine Mo August 31, 2021	Ionths Ended August 31, 2020		
	7.uguet e ., 2021	7.uguet e 1, 2020	7.tagaot o 1, 2021	. tuguet e 1, 2020		
Revenue	\$ 1,811	\$ 1,197	\$ 3,830	\$ 1,612		
Cost of Goods Sold	1,237	883	2,448	1,837		
Gross Margin	574	314	1,382	(225)		
OPERATING EXPENSES						
Legal and professional fees	925	1,500	5,425	6,200		
General and administrative	6,458	9,718	27,935	27,526		
Total operating expenses	7,383	11,218	33,360	33,726		
OTHER (INCOME) EXPENSE						
Interest expense	-	-	-	-		
(Gain) loss on derivative liability	480	<u> </u>	2,400	(600)		
Total other (income) expense	480	<u> </u>	2,400	(600)		
Net loss before taxes	(7,863)	(10,904)	(34,378)	(33,351)		
Income tax expense		<u> </u>				
Net loss	\$ (7,289)	\$ (10,904)	\$ (34,378)	\$ (33,351)		
Basic loss per						
common share	(\$0.00)	(\$0.00)	\$0.00	\$0.00		
Basic weighted average						
common shares	1,523,409,834	1,523,409,834	1,523,409,834	1,523,409,834		

# Itonis Inc. (formerly "Kenshou Inc.") Statement of Stockholders' Deficit (unaudited)

	Preferred	d Stock	Common	Stock	Additional Paid-in	Α	ccumulated	Sto	Total ockholders'
	Shares	Amount	Shares	Amount	Capital Deficit		Deficit		
Balance as of November 30, 2020	500,000	500	1,523,409,834	\$ 1,523,410	\$ 13,513,059	\$	(16,089,653)	\$	(1,052,684)
Net Loss for the Period							(34,378)		(34,378)
Balance as of August 31, 2021	500,000	500	1,523,409,834	\$ 1,523,410	\$ 13,513,059	\$	(16,124,031)	\$	(1,087,062)

# Itonis Inc. (Formerly "Kenshou Inc.") Cash Flow Statements (unaudited)

	For the Ni	ne Months Ended	For the Year Ended		
	Aug	ust 31, 2021	November 30, 2020		
Cash flows from operating activities:					
Net loss	\$	(34,378) \$	(48,509)		
Gain on decrease of share liability		2,400	(360)		
Issue of common stock to related parties		-	-		
Adjustments to reconcile net loss to net cash in operating activities:					
Changes in operating assets and liabilities					
Prepaid Expenses					
Inventory		2,297	(4,380)		
Capitalized License Fees		-	-		
Accounts Payable		-	-		
Accounts Payable Retated Party		-	-		
Income Taxes Payable		-	-		
Net cash used in operating activities		(29,681)	(53,249)		
Cash flows from investing activities:					
Net cash used in investing activities		-			
Cash flows from financing activities:					
Loans		30,000	53,300		
Stock for Debt		-	-		
Net cash provided by financing activities		30,000	53,300		
Net change in cash		319	51		
Cash, beginning of period		2,149	2,098		
Cash, end of period	\$	2,468 \$	2,149		
Supplementary disclosure of cash flow information:					
Cash paid for interest	\$	- \$			
Cash paid for taxes	\$	- \$	<u>-</u>		

# NOTE 1. DESCRIPTION OF BUSINESS AND ACCOUNTING POLICIES

<u>Description of Business</u> – Itonis, Inc. (formerly Kenshou Inc.) (the "Company" or "Itonis") was incorporated on July 5, 2005 as Kenshou Inc. under the laws of the State of Nevada. On December 2, 2005, the Company changed its name to Itonis Inc.

In 2012, the Company launched a new Itonis Pharmaceuticals division headed by Dr. Charles Hensley, Ph.D. to produce and market over the counter and prescription homeopathic preparations to treat both common ailments and chronic diseases. The Company has launched the retails sale of the Emesyl® nausea relief product. The Company has identified the market for its Emesyl® product line as the general public who suffers from nausea. The Emesyl® product is available at www.amazon.com.

Since then, the Company has organized its Itonis Holdings, Inc. subsidiary to own and manage the entirety of the Emesyl® nausea relief product line. Dr. Hensley has fully assigned all the patent rights in Emesyl® nausea relief to Itonis Holdings, Inc.

<u>Use of Estimates and Assumptions</u> - The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

<u>Basis of Presentation</u> - These financial statements present the balance sheets and the related statements of operations, cash flows and stockholders' deficit of Itonis, Inc.

<u>Fiscal Periods</u> – The Company's fiscal year-end is November 30.

<u>Cash and Cash Equivalents</u> - For the purpose of the statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to be cash equivalents. The carrying value of these investments approximates fair value.

•

<u>Inventory</u>- The Company has capitalized \$37,565 in product costs related to Emesyl™ which are being written off as product is sold.

Patent- The Company acquired all rights to the patent for Emesyl™.

<u>Accounts Payable-Related parties</u>- Amounts have been advanced by related parties to fund the operations of the Company. The advances are non-interest bearing, unsecured, and due on demand.

<u>Derivative liabilities</u> – The Company is contractually obligated to issue 1,200,000 more shares than it currently has issued. The values of these shares were originally recorded at their fair market value to determine the cost basis of the underlying transaction. The share liabilities are revalued at the end of each reporting period and the liabilities are adjusted to reflect current market value. The change in fair value is reflected separately in the Company's Statements of Operations. As of August 31, 2021, and November 30, 2020 the fair value of the obligated shares was \$ 3,360 and \$960.

Income Taxes - The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, "Income Taxes", which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Earnings (loss) Per Share - The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 "Earnings Per Share", Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.

.

<u>Fair Value of Financial Instruments</u> - Accounting Standards Codification ("ASC") 820, Fair Value Measurements and Disclosures, requires disclosing fair value to

the extent practicable for financial instruments that are recognized or unrecognized in the balance sheet. Fair value of financial instruments is the amount at which the instruments could be exchanged in a current transaction between willing parties. The Company considers the carrying amounts of cash, certificates of deposit, accounts receivable, accounts payable, notes payable, related party and other payables, customer deposits, and short term loans to approximate their fair values because of the short period of time between the origination of such instruments and their expected realization. The Company considers the carrying amounts of notes payable to approximate their fair values based on the interest rates of the instruments and the current market rate of interest.

# Recent Accounting Pronouncements-

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) in order to increase transparency and comparability among organizations by, among other provisions, recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. For public companies, ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 (including interim periods within those periods) using a modified retrospective approach and early adoption is permitted. In transition, entities August also elect a package of practical expedients that must be applied in its entirety to all leases commencing before the adoption date, unless the lease is modified, and permits entities to not reassess (a) the existence of a lease, (b) lease classification or (c) determination of initial direct costs, as of the adoption date, which effectively allows entities to carryforward accounting conclusions under previous U.S. GAAP. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, which provides entities an optional transition method to apply the guidance under Topic 842 as of the adoption date, rather than as of the earliest period presented. The Company adopted this new lease guidance during this fiscal year beginning December 1, 2020.

Company management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

•

### NOTE 2. GOING CONCERN

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of August 31, 2021, the Company has incurred cumulative net losses of over \$16,000,000 and used \$53,249 in operations for the period ended August 31, 2021. Under current operations the Company requires capital for its operational and marketing activities to take place. The Company's ability to raise additional capital through the future issuances of common stock is unknown. Obtaining additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the company cannot continue in existence

### NOTE 3. RELATED PARTY TRANSACTIONS

Management of the Company has made non-interest bearing, unsecured, due on demand cash advances and loans to the Company and has accrued amounts due an officer for services which total \$ 1,129,960 as of August 31, 2021.

## **NOTE 4. LEASES**

The Company rents its office facilities on a month to month basis from a related party for \$2,212 per month.

The Company wrote off its Right to Use Real Estate asset and related Lease Liability when it moved to new offices.

### NOTE 5. LOANS PAYABLE

Through August 31, 2021, the Company had received \$ 877,141 in short-term loans from related parties. These loans are due on demand and are interest free.

\$276,134 of these notes were issued with a conversion feature that allows the notes to be exchanged for common shares at 75% of the market price upon conversion. \$30,000 of these notes were issued during 2021 and \$52,500 during 2020.

•

## NOTE 6. STOCKHOLDERS' DEFICIT

## **Preferred Stock:**

The Company has authorized 5,000,000 shares of preferred stock

On June 4, 2012, the Board of Directors of the Company approved the designation of Series A preferred shares which provides voting rights equal to the greater of (i) One Thousand (1,000) votes for each share of Series A Preferred Stock or (ii) the number of votes equal to the number of all outstanding shares of Common Stock, plus one additional vote such that the holders of Series A Preferred Stock shall always constitute a majority of the voting rights of the Corporation.

500,000 shares of Preferred Shares were issued to related parties June 5, 2015.

### Common Stock:

On July 6, 2015 shareholders of record holding over 50% of the issued and outstanding shares of the Company approved the increase in authorized shares from 1,000,000,000 to 1,800,000,000 shares. There were 1,523,409,834 shares of common stock outstanding as of August 31, 2021.

#### **Share Transactions:**

# **Common Stock**

There were no share transactions during 2021 and 2020.

## NOTE 7. INCOME TAXES

Deferred tax assets are comprised of the benefits of loss carry forwards for the Fiscal year ended August 31, 2021 of approximately \$317,000. Losses prior to December 1, 2009 were incurred in different industries and in foreign jurisdictions and their use would be limited to offset federal and state income taxes. These losses would also be limited by the change of control provisions in Section 382 and 383 of the Internal Revenue Code.

.

Management has concluded that the use of these loss carry forwards would be severely restricted and the effect of these losses is not included in this report.

Deferred taxes arise from temporary differences in the recognition of certain expenses for tax and financial reporting purposes. As of August 31, 2021, the company had significant timing differences for tax reporting purposes for the non-cash recognition of liabilities due for committed shares in excess of authorized shares, shares issued for services, and shares issued for compensation. The expenses related to these liabilities are treated as permanent differences between financial and tax reporting.

At August 31, 2021, management determined that realization of these loss carry forward benefits is not assured and has provided a valuation allowance for the entire amount of such benefits,

ASC 740 clarifies the accounting for uncertainty in income taxes and prescribes a recognition threshold, measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. Under ASC 740, we are required to recognize in the financial statements the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods and disclosure. Our policy is to record interest and penalties related to unrecognized tax benefits in income tax expense. There were no unrecognized tax benefits recorded as of August 31, 2021.

.